Carl Zeiss Meditec AG (CZMWF)
USD 65.07
(12.44%)
USD 65.07
(12.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 327.13 Million EUR | 3.57% |
| 2022 | 413.08 Million EUR | 18.56% |
| 2021 | 348.41 Million EUR | 68.64% |
| 2020 | 206.6 Million EUR | -13.22% |
| 2019 | 238.06 Million EUR | 32.75% |
| 2018 | 179.34 Million EUR | -1.85% |
| 2017 | 182.72 Million EUR | 24.84% |
| 2016 | 146.36 Million EUR | 26.19% |
| 2015 | 115.99 Million EUR | -1.27% |
| 2014 | 117.48 Million EUR | -23.8% |
| 2013 | 154.17 Million EUR | 25.45% |
| 2012 | 122.9 Million EUR | 18.67% |
| 2011 | 103.56 Million EUR | 19.39% |
| 2010 | 86.74 Million EUR | 14.01% |
| 2009 | 76.08 Million EUR | 12.17% |
| 2008 | 67.83 Million EUR | -3.59% |
| 2007 | 70.35 Million EUR | 46.32% |
| 2006 | 48.08 Million EUR | 34.57% |
| 2005 | 35.73 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 108.2 Million EUR | 84.64% |
| 2024 Q1 | 58.6 Million EUR | -51.01% |
| 2024 Q3 | 54.69 Million EUR | -49.73% |
| 2023 Q4 | 119.61 Million EUR | -11.8% |
| 2023 Q2 | 97.46 Million EUR | 28.41% |
| 2023 Q1 | 75.9 Million EUR | -47.39% |
| 2023 Q3 | 135.61 Million EUR | 39.14% |
| 2023 FY | 427.81 Million EUR | 3.57% |
| 2022 FY | 413.08 Million EUR | 18.56% |
| 2022 Q1 | 56.1 Million EUR | -30.24% |
| 2022 Q2 | 122.24 Million EUR | 117.9% |
| 2022 Q3 | 90.47 Million EUR | -25.99% |
| 2022 Q4 | 144.28 Million EUR | 59.48% |
| 2021 Q1 | 68.4 Million EUR | -28.6% |
| 2021 Q4 | 80.41 Million EUR | -32.1% |
| 2021 Q3 | 118.43 Million EUR | 45.96% |
| 2021 Q2 | 81.13 Million EUR | 18.62% |
| 2021 FY | 348.41 Million EUR | 68.64% |
| 2020 Q2 | 43.14 Million EUR | -26.5% |
| 2020 FY | 206.6 Million EUR | -13.22% |
| 2020 Q4 | 95.8 Million EUR | 968.18% |
| 2020 Q3 | 8.96 Million EUR | -79.21% |
| 2020 Q1 | 58.7 Million EUR | -15.26% |
| 2019 Q1 | 42 Million EUR | -29.1% |
| 2019 Q2 | 50.26 Million EUR | 19.67% |
| 2019 Q3 | 76.56 Million EUR | 52.34% |
| 2019 Q4 | 69.26 Million EUR | -9.53% |
| 2019 FY | 238.06 Million EUR | 32.75% |
| 2018 FY | 179.34 Million EUR | -1.85% |
| 2018 Q1 | 39.1 Million EUR | -9.33% |
| 2018 Q2 | 46.31 Million EUR | 18.44% |
| 2018 Q3 | 37.13 Million EUR | -19.81% |
| 2018 Q4 | 59.24 Million EUR | 59.52% |
| 2017 Q4 | 43.12 Million EUR | -5.0% |
| 2017 Q3 | 45.39 Million EUR | -6.14% |
| 2017 Q2 | 48.36 Million EUR | 5.59% |
| 2017 Q1 | 45.8 Million EUR | 6.29% |
| 2017 FY | 182.72 Million EUR | 24.84% |
| 2016 Q1 | 28.78 Million EUR | -13.35% |
| 2016 Q3 | 29.09 Million EUR | -35.9% |
| 2016 Q4 | 43.09 Million EUR | 48.09% |
| 2016 FY | 146.36 Million EUR | 26.19% |
| 2016 Q2 | 45.39 Million EUR | 57.68% |
| 2015 FY | 115.99 Million EUR | -1.27% |
| 2015 Q4 | 33.22 Million EUR | -1.9% |
| 2015 Q2 | 19.63 Million EUR | -32.92% |
| 2015 Q1 | 29.26 Million EUR | 36.18% |
| 2015 Q3 | 33.86 Million EUR | 72.51% |
| 2014 Q2 | 36.29 Million EUR | 8.88% |
| 2014 FY | 117.48 Million EUR | -23.8% |
| 2014 Q4 | 21.49 Million EUR | -18.47% |
| 2014 Q3 | 26.35 Million EUR | -27.38% |
| 2014 Q1 | 33.33 Million EUR | -25.76% |
| 2013 Q1 | 39.67 Million EUR | 15.63% |
| 2013 FY | 154.17 Million EUR | 25.45% |
| 2013 Q2 | 32.87 Million EUR | -17.15% |
| 2013 Q3 | 36.73 Million EUR | 11.75% |
| 2013 Q4 | 44.9 Million EUR | 22.24% |
| 2012 Q4 | 34.31 Million EUR | 24.8% |
| 2012 Q1 | 28.27 Million EUR | 1.35% |
| 2012 FY | 122.9 Million EUR | 18.67% |
| 2012 Q3 | 27.49 Million EUR | -16.23% |
| 2012 Q2 | 32.81 Million EUR | 16.06% |
| 2011 Q3 | 24.34 Million EUR | -10.87% |
| 2011 Q1 | 24.01 Million EUR | -10.38% |
| 2011 Q2 | 27.31 Million EUR | 13.75% |
| 2011 Q4 | 27.9 Million EUR | 14.61% |
| 2011 FY | 103.56 Million EUR | 19.39% |
| 2010 FY | 86.74 Million EUR | 14.01% |
| 2010 Q2 | 20.59 Million EUR | 10.27% |
| 2010 Q3 | 20.67 Million EUR | 0.36% |
| 2010 Q4 | 26.79 Million EUR | 29.6% |
| 2010 Q1 | 18.68 Million EUR | -16.86% |
| 2009 Q2 | 17.39 Million EUR | -19.04% |
| 2009 Q3 | 14.73 Million EUR | -15.3% |
| 2009 FY | 76.08 Million EUR | 12.17% |
| 2009 Q4 | 22.46 Million EUR | 52.49% |
| 2009 Q1 | 21.48 Million EUR | 0.0% |
| 2008 FY | 67.83 Million EUR | -3.59% |
| 2007 FY | 70.35 Million EUR | 46.32% |
| 2006 FY | 48.08 Million EUR | 34.57% |
| 2005 FY | 35.73 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.16 Million USD | -27999.157% |
| Ansell Limited | 129.3 Million USD | -153.005% |
| Ansell Limited | 129.3 Million USD | -153.005% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 31.13 Million USD | -950.594% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.59 Million USD | 20601.084% |
| Psykey, Inc. | -797.5 Thousand USD | 41119.982% |
| ConvaTec Group Plc | 262.7 Million USD | -24.528% |
| ConvaTec Group Plc | 262.7 Million USD | -24.528% |
| Encision Inc. | -640.78 Thousand USD | 51152.54% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 230786.129% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 297685.736% |
| Innovative MedTech Inc. | -4.27 Million USD | 7753.958% |
| LifePoint, Inc. | -7.49 Million USD | 4464.59% |
| Medite Cancer Diagnostics, Inc. | -6.48 Million USD | 5148.395% |
| Paradigm Medical Industries, Inc. | 330 Thousand USD | -99032.121% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -122.89 Thousand USD | 266302.295% |
| Reflect Scientific, Inc. | -467.27 Thousand USD | 70108.86% |
| SmileDirectClub, Inc. | -241.15 Million USD | 235.653% |
| Sector 10, Inc. | -39.84 Thousand USD | 821142.064% |
| Shandong Weigao Group Medical Polymer Company Limited | 319.6 Million USD | -2.356% |
| SheerVision, Inc. | 155.72 Thousand USD | -209971.536% |
| United Health Products, Inc. | -2.42 Million USD | 13581.588% |
| Vasamed, Inc. | 4.74 Million USD | -6798.253% |
| Wearable Health Solutions, Inc. | -2.29 Million USD | 14359.629% |
| Yubo International Biotech Limited | -1.2 Million USD | 27243.193% |